1
|
Alvarez F, Berg PA, Bianchi FB, et al:
International Autoimmune Hepatitis Group Report: review of criteria
for diagnosis of autoimmune hepatitis. J Hepatol. 31:929–938. 1999.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Seo S, Toutounjian R, Conrad A, et al:
Favorable outcomes of autoimmune hepatitis in a community clinic
setting. J Gastroenterol Hepatol. 23:1410–1414. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Czaja AJ: Autoimmune liver disease. Curr
Opin Gastroenterol. 19:232–242. 2003. View Article : Google Scholar
|
4
|
Wiesner RH, Demetris AJ, Belle SH, et al:
Acute allograft rejection: incidence, risk factors, and impact on
outcome. Hepatology. 28:638–645. 1998. View Article : Google Scholar : PubMed/NCBI
|
5
|
Feld JJ, Dinh H, Arenovich T, et al:
Autoimmune hepatitis: effect of symptoms and cirrhosis on natural
history and outcome. Hepatology. 42:53–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Czaja AJ: Diverse manifestations and
evolving treatments of autoimmune hepatitis. Minerva Gastroenterol
Dietol. 51:313–333. 2005.PubMed/NCBI
|
7
|
Floreani A, Niro G, Rosa Rizzotto E, et
al: Type I autoimmune hepatitis: clinical course and outcome in an
Italian multicentre study. Aliment Pharmacol Ther. 24:1051–1057.
2006. View Article : Google Scholar : PubMed/NCBI
|
8
|
Parker DR and Kingham JG: Type I
autoimmune hepatitis is primarily a disease of later life. QJM.
90:289–296. 1997. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ichai P, Duclos-Vallée JC, Guettier C, et
al: Usefulness of corticosteroids for the treatment of severe and
fulminant forms of autoimmune hepatitis. Liver Transpl.
13:996–1003. 2007. View
Article : Google Scholar : PubMed/NCBI
|
10
|
Johnson PJ and McFarlane IG: Meeting
report: International Autoimmune Hepatitis Group. Hepatology.
18:998–1005. 1993. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ngu JH, Gearry RB, Frampton CM, et al:
Mortality and the risk of malignancy in autoimmune liver diseases:
a population-based study in Canterbury, New Zealand. Hepatology.
55:522–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hoeroldt B, McFarlane E, Dube A, et al:
Long-term outcomes of patients with autoimmune hepatitis managed at
a nontransplant center. Gastroenterology. 140:1980–1989. 2011.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Manns MP, Woynarowski M, Kreisel W, et al:
Budesonide induces remission more effectively than prednisone in a
controlled trial of patients with autoimmune hepatitis.
Gastroenterology. 139:1198–1206. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Al-Chalabi T, Underhill JA, Portmann BC,
et al: Effects of serum aspartate aminotransferase levels in
patients with autoimmune hepatitis influence disease course and
outcome. Clin Gastroenterol Hepatol. 6:1389–1395. 2008. View Article : Google Scholar
|
15
|
Ngu JH, Gearry RB, Frampton CM and Stedman
CA: Predictors of poor outcome in patients with autoimmune
hepatitis: A population-based study. Hepatology. 57:2399–2406.
2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Czaja AJ and Carpenter HA: Distinctive
clinical phenotype and treatment outcome of type 1 autoimmune
hepatitis in the elderly. Hepatology. 43:532–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Miyake Y, Iwasaki Y, Takaki A, et al:
Clinical features of Japanese elderly patients with type 1
autoimmune hepatitis. Intern Med. 46:1945–1949. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Czaja AJ: Behavior and significance of
autoantibodies in type 1 autoimmune hepatitis. J Hepatol.
30:394–401. 1999. View Article : Google Scholar : PubMed/NCBI
|
19
|
Baeres M, Herkel J, Czaja AJ, et al:
Establishment of standardised SLA/LP immunoassays: specificity for
autoimmune hepatitis, worldwide occurrence, and clinical
characteristics. Gut. 51:259–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zauli D, Ghetti S, Grassi A, et al:
Anti-neutrophil cytoplasmic antibodies in type 1 and type 2
autoimmune hepatitis. Hepatology. 25:1105–1107. 1997. View Article : Google Scholar : PubMed/NCBI
|
21
|
Czaja AJ, Donaldson PT and Lohse AW:
Antibodies to soluble liver antigen/liver pancreas and HLA risk
factors for type 1 autoimmune hepatitis. Am J Gastroenterol.
97:413–419. 2002. View Article : Google Scholar : PubMed/NCBI
|
22
|
Toda G, Zeniya M, Watanabe F, et al:
Present status of autoimmune hepatitis in Japan - correlating the
characteristics with international criteria in an area with a high
rate of HCV infection. Japanese National Study Group of Autoimmune
Hepatitis. J Hepatol. 26:1207–1212. 1997. View Article : Google Scholar : PubMed/NCBI
|
23
|
Czaja AJ and Freese DK; American
Association for the Study of Liver Disease. Diagnosis and treatment
of autoimmune hepatitis. Hepatology. 36:479–497. 2002. View Article : Google Scholar
|
24
|
Krawitt EL: Autoimmune hepatitis. N Engl J
Med. 354:54–66. 2006. View Article : Google Scholar
|